Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1: Allegations - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the efficacy and tolerability results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical, commercial, and competitive prospects than what was communicated to investors [1]. - The lawsuit asserts that the company exaggerated its prospects for finding a strategic partner to develop pemvidutide, leading to materially false and misleading public statements [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as December 1, 2023, to April 26, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is July 5, 2024, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that inflate stock prices [3].